Pancragen for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Pancragen for Health & Longevity

Created on 09/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A four-amino-acid peptide directed at the pancreas, proposed to adjust which genes pancreatic tissue reads. The case rests on one small controlled study in older adults with type 2 diabetes, plus monkey, rat and cell work — almost all from the one institute that developed and licenses it. No adverse event has been systematically recorded in any human study. (Full Review)

Protocol

Standard course as used by practitioners
Oral capsules daily, 10 to 20 days
Repeated two to three times yearly, following the protocols of the institute that licenses the commercial product.
Best time of day
Morning, empty stomach
20 to 30 minutes before food; gut peptide transporters compete with dietary protein fragments. No timing comparison has been tested.
Published research dosing differs from commercial dosing
50 micrograms intramuscularly, 10 days (primates)
Commercial capsules are labeled at 10 to 20 milligrams total content, the tetrapeptide an undisclosed fraction.
Time to effect
Glucose and insulin measures
Days to weeks
The interval over which metabolic endpoints were measured in older adults with type 2 diabetes.
Within a course
10 days
Primate work showed changes in glucose clearance and insulin output within a 10-day course.
Effect persistence after stopping
3 weeks, partial
In old monkeys the improvement in pancreatic endocrine response was partially retained three weeks after the last dose.

Benefits

Contraindications
  • Pregnancy and lactation, at any stage
  • Autoimmune type 1 diabetes, and latent autoimmune diabetes in adults
  • Documented hypoglycemia unawareness, or HbA1c below 6.5% while on insulin or a sulfonylurea
  • Acute pancreatitis, active or within the preceding 90 days
  • Personal history of pancreatic cancer, or of pre-cancerous pancreatic changes
  • Known hypersensitivity to the peptide or to excipients in a specific preparation
    •
Key Interactions
  • Insulin and insulin secretagogues (drugs prompting insulin release): insulin, sulfonylureas (glimepiride, glipizide, glibenclamide), meglitinides (repaglinide, nateglinide)
  • Other prescription glucose-lowering agents: glucagon-like peptide-1 receptor agonists (semaglutide, liraglutide), sodium-glucose cotransporter-2 inhibitors (empagliflozin, dapagliflozin)
  • Over-the-counter medications: high-dose niacin, high-dose salicylates (aspirin, salsalate)
  • Supplements with additive glucose-lowering effects: berberine, chromium picolinate, alpha-lipoic acid, Gymnema sylvestre, cinnamon extract
  • Other interventions: prolonged fasting, ketogenic or very-low-carbohydrate eating, prolonged endurance exercise

Risk & Side Effects

  • Low: Additive blood glucose lowering and hypoglycemia; substandard, contaminated or misidentified product from unregulated sellers
  • Speculative: Proliferative and cell-death-resisting signaling in pancreatic tissue; hypersensitivity and injection-site reactions

Monitoring

Marker Target Why
Fasting glucose 75–85 mg/dL Primary endpoint and the earliest hypoglycemia signal
HbA1c 4.9–5.3% Three-month glycemic average; confirms a real shift rather than a single low reading
Fasting insulin 2–5 µIU/mL Detects the raised insulin output the peptide was reported to reduce
HOMA-IR Below 1.0 Calculated insulin resistance index; the endpoint the human study reported
C-peptide (fasting) 0.8–2.0 ng/mL Indicates how much insulin the pancreas itself produces, distinguishing residual function from exogenous insulin
Amylase and lipase No functional target is established; track stability against the individual's own pre-course values Screens for pancreatic inflammation before and during a course
eGFR and liver enzymes eGFR above 90 mL/min/1.73 m²; ALT below 25 U/L Establishes clearance capacity for co-administered glucose-lowering drugs
hsCRP Below 0.5 mg/L Tracks the low-grade inflammation that accompanies insulin resistance

Cadence: Pre-course panel before the first course; fasting glucose at day 5 and day 10 of a course; full glycemic panel at course completion and again 8 to 12 weeks afterwards; repeat before each subsequent course.

Qualitative Assessment

  • Post-meal energy stability, particularly the absence of an afternoon slump following a carbohydrate-containing lunch
  • Hypoglycemic symptoms — tremor, sweating, disproportionate hunger — which signal additive glucose lowering rather than benefit
  • Sleep continuity and consistency of sleep timing, given the melatonin association reported in the same population
  • Abdominal comfort after meals, since new upper abdominal pain radiating to the back is a stop signal
  • Injection-site appearance where an injectable preparation is used, tracking firm swelling or persistent redness
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.